Mainstream

Sangamo therapeutics misses top line and bottom line estimates; reaffirms fy25 outlook

Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook

Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook

Post ContentsgmoRead More

You might also be interested in reading Strategy’s Saylor signals BTC buy as preferred dividend pay date vote looms.

May 13, 2025
In Mainstream